Drug class profile · refreshed daily from federal data

Muscle Relaxant

6 molecules in this class, $114.3M combined CY2024 Part D spend across 5.9M claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Muscle Relaxant class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 6tracked in Part D
CY24 Part D spend: $114.3Mcombined across class
Total Rx claims: 5.9M2.6M unique beneficiaries
Generic mfrs (active): 55across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Methocarbamol

Brand: ATMEKSI · 5.1M Part D claims (CY24) · 2.3M beneficiaries · First FDA approval: 1959-06-16

18 generic mfrs 0 plans require PA

Low NADAC$0.038

→

Avg plan cost$0.620

Part D spend $65.6M 16× spread, current vs floor

Class share

57%

of class CY24 spend

View profile →

Chlorzoxazone

95K Part D claims (CY24) · 33K beneficiaries · First FDA approval: 2011-08-22

11 generic mfrs 38 plans require PA

Low NADAC$0.231

→

Avg plan cost$0.870

Part D spend $24.2M 4× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Metaxalone

108K Part D claims (CY24) · 47K beneficiaries · First FDA approval: 2013-05-31

6 generic mfrs 34 plans require PA

Low NADAC$0.393

→

Avg plan cost$0.681

Part D spend $12.6M 2× spread, current vs floor

Class share

11%

of class CY24 spend

View profile →

Carisoprodol

Brand: Soma · 515K Part D claims (CY24) · 114K beneficiaries · First FDA approval: 1995-11-01

13 generic mfrs 49 plans require PA

Low NADAC$0.066

→

Avg plan cost$0.759

Part D spend $8.4M 12× spread, current vs floor

Class share

of class CY24 spend

View profile →

Orphenadrine

108K Part D claims (CY24) · 67K beneficiaries · First FDA approval: 1998-06-19

7 generic mfrs 25 plans require PA

Low NADAC$0.475

→

Avg plan cost$3.31

Part D spend $3.5M 7× spread, current vs floor

Class share

of class CY24 spend

View profile →

Methocarbamol Tablets

Brand: Methocarbamol · — Part D claims (CY24) · First FDA approval: 2018-05-15

Brand-only (no generics) 112 plans require PA

Low NADAC$0.039

→

Avg plan cost$0.041

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.